Half-Year 2022 Financial Performance

Small Molecules Financial and operational performance in H1 2022 Lonza Lower sales arising from phasing of major shipments to contracted customers - Long-term pipeline reflected by sustained momentum in new program signings 288m Sales (CHF) 86m CORE EBITDA (CHF) 29.9% CORE EBITDA Margin -21.3%¹ - -13.1% +2.6ppts Bordered figures are a comparison vs. Half-Year 2021 1 Sales growth % is at constant exchange rate (CER) Capacity expansions in Nansha (CN), Bend (US) and Tampa (US) successfully executed and currently in ramp up phase - Margin increase compared to H1 2021, driven by growth projects, high utilization and portfolio mix CORE definition: See appendix 20 20

View entire presentation